Segmental Reporting (Tables)

6 Months Ended

Jun. 30, 2014

Segment Reporting [Abstract]

Schedule of Segment Revenue from Major Products

6 months to,	June 30,	June 30,
	2014	2013
	$’M	$’M
	___________	___________
VYVANSE	710.7	598.7
ELAPRASE	280.7	263.5
LIALDA/MEZAVANT	272.5	238.0
REPLAGAL	244.8	228.1
CINRYZE	215.5	-
INTUNIV	182.3	168.1
ADDERALL XR	184.9	212.1
VPRIV	176.6	164.1
FIRAZYR	163.9	91.2
PENTASA	135.5	144.6
FOSRENOL	88.1	84.4
XAGRID	55.0	49.9
Other product sales	67.2	63.4
	____________	____________
Total product sales	2,777.7	2,306.1
	____________	____________